Lab-Grown skin patch could heal wounds in 'Butterfly Children'

NCT ID NCT07193134

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein. It aims to safely heal wounds in 9 people with recessive dystrophic epidermolysis bullosa (RDEB), a rare disease that causes fragile, blistering skin. The graft is applied after wound cleaning and temporary donor skin, and researchers will monitor healing, pain, and itching for a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

genetically modified skin graft made from the patient's own cells

What this could lead to

If it works, this could provide a lasting way to heal wounds and reduce pain and itching for people with RDEB.

What could go wrong

This is an early-phase trial with only 9 participants, so results may not apply to everyone. The graft uses a virus to modify cells, which carries unknown long-term risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RDEB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Collagen Diseases Congenital Abnormalities connective tissue disorder epidermolysis bullosa epidermolysis bullosa dystrophica hereditary disease hereditary skin disorder recessive dystrophic epidermolysis bullosa Skin Abnormalities Skin and Connective Tissue Diseases skin disorder vesiculobullous skin disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Hospital for Sick Children (SickKids)

    RECRUITING

    Toronto, Ontario, M5G 1E8, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••